Table 4.
Unadjusted OR | P | 95% CI |
||
---|---|---|---|---|
Lower Limit | Upper Limit | |||
Univariate | ||||
non-RIT versus RIT | 0.92 | 0.68 | 0.61 | 1.39 |
PRA category | 0.96 | 0.77 | 0.76 | 1.23 |
follow-up (days) | 1.00 | 0.64 | 1.00 | 1.00 |
vintage | 1.00 | 0.55 | 1.00 | 1.00 |
DD versus LD | 1.53 | 0.05 | 1.01 | 2.34 |
induction agent | 1.00 | 0.98 | 0.79 | 1.26 |
lymphocyte depletion | 1.34 | 0.16 | 0.89 | 2.04 |
race | 0.90 | 0.27 | 0.74 | 1.09 |
age (years) | 1.02 | 0.02 | 1.00 | 1.03 |
gender | 1.45 | 0.08 | 0.95 | 2.21 |
DM and/or HTNa | 1.12 | 0.07 | 0.99 | 1.28 |
acute rejection | 1.57 | 0.08 | 0.95 | 2.59 |
Multivariate | ||||
lymphocyte depletion | 1.18 | 0.47 | 0.75 | 1.87 |
DD versus LD | 1.37 | 0.16 | 0.88 | 2.12 |
age (years) | 1.02 | 0.06 | 1.00 | 1.03 |
gender | 1.52 | 0.06 | 0.98 | 2.34 |
DM and/or HTNa | 1.09 | 0.27 | 0.94 | 1.25 |
acute rejection | 1.64 | 0.06 | 0.98 | 2.76 |
The reference group for diabetes mellitus and/or hypertension is all other kidney diseases (glomerulonephritis, cystic, other, and unknown). The reference group for gender is male. DD, deceased donor; LD, living donor; OR, odds ratio; PRA, panel reactive antibodies; RIT, rituximab; DM, diabetes mellitus; HTN, hypertension; CI, confidence interval.
The presence of diabetes mellitus and/or hypertension as the cause of end-stage renal disease.